News
TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results